Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03520842 · ClinicalTrials.gov registry record · Phase 2
Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT03520842: Completed Phase 2 study, sponsored by Stanford University.
NCT03520842 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03520842, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
This phase II trial studies how well regorafenib works together with methotrexate in treating participants with metastatic non-squamous non-small cell lung cancer with tumors that harbor a KRAS mutation. Regorafenib is a targeted therapy that works on different cancer pathways to stop the growth of tumor cells and stop them from spreading. Methotrexate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving regorafenib and methotrexate together may work in treating participants with KRAS mutated non-small cell lung cancer.
Interventions
- DRUG Regorafenib
- DRUG Methotrexate
- OTHER Pharmacokinetic Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-08-14 |
| Est. Completion | 2022-06-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03520842
The ClinicalTrials.gov registry entry for NCT03520842 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Regorafenib is the first listed.
NCT03520842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03520842 about?
NCT03520842 is a clinical study titled "Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer". This phase II trial studies how well regorafenib works together with methotrexate in treating participants with metastatic non-squamous non-small cell lung cancer with tumors that harbor a KRAS mutation. Regorafenib is a targeted therapy that works on different cancer pathways to stop the growth of ...
What is the current status of trial NCT03520842?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2018-08-14. Estimated completion is 2022-06-15.
What interventions are being tested in trial NCT03520842?
The interventions under investigation include: Regorafenib (DRUG), Methotrexate (DRUG), Pharmacokinetic Study (OTHER).
Who is sponsoring clinical trial NCT03520842?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.